Introduction
============

Nasopharyngeal carcinoma (NPC), known as an endemic malignancy in southeast Asia, southern China, and Taiwan, is caused by multifactorial etiologies including infection by Epstein-Barr virus (EBV), environmental factors (e.g., smoking and consumption of preserved food), and hereditary factors [@B1]-[@B4]. According to the present World Health Organization (WHO) classification, several histological subtypes of NPC are available including squamous-cell carcinoma (SCC), nonkeratinizing carcinoma (differentiated or undifferentiated), and basaloid SCC [@B5]. Approximately 99% of NPCs are classified as differentiated or undifferentiated nonkeratinizing carcinoma in endemic areas, showing a strong association with EBV infection [@B5], [@B6]. Radiotherapy is still the first-line therapy for early-stage NPC, whereas cisplatin-based chemoradiotherapy is currently recommended for more advanced disease stages involving a diminished distant metastatic rate and improved locoregional control [@B7]-[@B10]. However, a considerable proportion of patients develop a certain degree of resistance to chemoradiotherapy, which may result in locoregional recurrence and distant metastasis in certain patients [@B9]-[@B11]. Hence, identifying prognostic biomarkers for improving the treatment efficacy and risk stratification is crucial, and this can facilitate the development of novel and personalized therapeutic treatment for patients with NPC.

We reassessed a published transcriptome of NPC (GSE12452) to explore prominent differentially expressed genes. We identified *glutamate decarboxylase 1* (*GAD1*) as a prominently upregulated gene among the pathways associated with glutamate decarboxylase activity (GO:0004351). Glutamine was demonstrated to play a role in tumor metabolism through tricarboxylic acid cycle-dependent and independent pathways [@B12]-[@B14]. Glutamine metabolism alteration is extremely crucial and has led to the development of prognostic adjunct and therapeutic targets for cancer therapy [@B12]-[@B14]. In addition to playing a role in the synthesis of the amino acids proline and arginine, glutamine-derived glutamate plays a central role in the synthesis of the antioxidant glutathione, which is pivotal in managing oxidative stress in cancer [@B15]. GAD1 is present in the GABAergic neurons in the CNS, functioning as a rate-limiting enzyme which catalyzes the decarboxylation of glutamate to γ-aminobutyric acid (GABA) [@B16]. Human beings have three known isoforms of GAD: GAD1, 25, and 67 (67, 25, and 65 kDa, respectively) [@B17], [@B18]. GAD1 is involved in certain psychiatric diseases and insulin-dependent diabetes mellitus [@B19], [@B20]. Considerably high GAD1 expression has been recently observed in neoplasms such as oral SCC (OSCC), colorectal cancer, breast cancer, and gastric cancer [@B16], [@B21], [@B22]. In addition, GAD1 might be a prostate-specific tissue biomarker because it is considerably overexpressed in patients with metastatic prostate cancers [@B23], [@B24]. GAD1 and GABA were also found to play a role in regulating cancer cells, particularly in the proliferation of stem cells [@B25]. However, little is known about the role of GAD1 expression in NPC.

It has never been comprehensively investigated the significance of GAD1 expression in a well-established cohort of NPC tissues, as well as its association with different clinicopathological variables. Therefore, we analyzed GAD1 immunoexpression in NPC specimens and its correlation with various clinicopathological factors and prognostic implications.

Materials and Methods
=====================

Analysis of published transcriptome data sets
---------------------------------------------

To identify genes that play a critical role in the pathogenesis of NPC, we re-examined the transcriptome data set published in the Gene Expression Omnibus (GSE12452) of NPC tissues (n = 31) versus non-tumorous nasopharyngeal epithelial tissues (n = 10) enriched through laser-capture microdissection for target cells [@B26]-[@B29]. All probe sets were analyzed without filtering or preselection by means of importing raw CEL files of the Affymetrix HUMAN Genome U133 Plus 2.0 microarray platform into Nexus Expression 3 software (BioDiscovery). Supervised functional profiling and comparative analysis were done, as described previously, to identify prominent differentially expressed genes by emphasizing pathways involving glutamate decarboxylase activity in Gene Ontology (GO:0004351) [@B27]-[@B29]. We identified those that with *p*\< 0.01 and a log2-transformed expression fold change \> 0.1 for further evaluation.

Patients and tumor specimens
----------------------------

All institutional review board (IRB)-approved NPC tissues were procured for the study (IRB10501-006). In total, 146 formalin-fixed, paraffin-embedded biopsy specimens were retrieved from patients with NPC at Chi-Mei Medical Center between January 1993 and December 2002. Of these patients, 10 with systemic involvement and 12 who did not accomplish the standard treatment course or were lost to follow-up were excluded. The remaining 124 patients were excluded from this retrospective study. No events of distant metastases were identified at the initial diagnosis for all of these patients. Two pathologists (TJC and HLH) reappraised the histologic subtypes based on the criteria of the current WHO classification [@B5]. Tumor staging was re-examined according to the seventh American Joint Committee on Cancer (AJCC) system [@B30].

Immunohistochemical staining and assessment of GAD1 expression
--------------------------------------------------------------

Tissue sections (thickness = 3 μm) were obtained from paraffin-embedded blocks. Deparaffinized slides were then rehydrated with ethanol and heated using microwave treatment for retrieving antigen epitopes in 10 mM citrate buffer (pH 6) for 7 minutes. Furthermore, 3% H2O2 was used to quench endogenous peroxidase. The slides were washed for 15 minutes by using Tris-buffered saline and then incubated with a primary polyclonal antibody targeting GAD1 (1:100; Clone EPR2550, Abcam) for 1 hour. A ChemMate EnVision kit (DAKO, K5001, Carpinteria, CA) was applied for identifying primary antibodies. After their incubation with the secondary antibody for 30 minutes and 3,3-diaminobenzidine for 5 minutes, the slides were counterstained with hematoxylin. Furthermore, a human lung tissue-containing respiratory epithelium sample was used as the positive control, according to the manufacturer\'s recommendation, and rabbit serum IgG-replacing primary antibody served as the negative control. Blinded to the clinical and follow-up information, two pathologists (TJC & HLH) examined GAD1 immunoexpression by using a multiheaded microscope to reach a consensus on the H score, as reported in previous studies [@B27]-[@B29]. Those that express both cytoplasmic and nuclear staining are determined as immunopositive. In brief, we calculated the score by using the following equation: *H score* = *∑Pi (i + 1*), where *i*is the intensity (range, 0-3) and *Pi*is the percentage of stained tumor cells varying from 0% to 100%. Tumors with higher H scores than the median values of all examined cases were classified as having high expression.

Treatment and follow-up
-----------------------

In total, 114 of the 124 patients with NPC were regularly monitored after undergoing radiotherapy until death or their final appointment (mean follow-up duration, 67 months; range, 3-141 months). All 124 patients completed the radiotherapy course according to the published protocol, with a daily fractionation of 180-200 cGy and five fractions weekly to reach a total dose of no less than 7000 cGy [@B31]. For those with stage II-IV diseases, at least three cycles of cisplatin-based chemotherapy were adopted. Nonetheless, one patient with stage II and four patients with stage IV diseases did not receive current chemotherapy but only radiation therapy because of their poor general health condition. The method of administering radiotherapy was generally uniform in this study. However, seven patients treated in the earlier phase of the cohort were unavailable for instant post-therapy image evaluations that could be used to establish the baseline for determining the treatment effect. Moreover, 110 complete and 7 partial tumor regressions determined through the previously reported methods were adjusted according to the WHO criteria [@B32].

Statistical analysis
--------------------

SPSS 14 software was used for statistical analyses, and the chi-squared and Mann-Whitney U test was used for evaluating the associations between the GAD1 expression status and various clinicopathological variables and the differential expression between primary and metastatic lesions, respectively. The analytic endpoints were disease-specific survival (DSS), distant-metastasis-free survival (DMeFS), and local recurrence-free survival (LRFS), calculated from the start date of radiotherapy to the date the event developed. Moreover, we used the Kaplan-Meier method to plot survival curves and performed log-rank tests to evaluate prognostic significance levels. Multivariate analysis was done using the Cox proportional hazards model. Two-sided tests were performed, with *p* \< 0.05 considered significant for all analyses.

Results
=======

*GAD1* serves as the only differentially upregulated gene involved in the glutamate decarboxylase activity
----------------------------------------------------------------------------------------------------------

From the data set of 31 NPC cases in the published transcriptome, we analyzed eight probes covering two genes participated in glutamate decarboxylase activity. Among these genes, *GAD1* was the only differentially expressed gene with a significant statistical power (*p* = 0009) and considerable log2-transformed expression (log2 ratio = 0.3746) that met the selection criteria for further evaluation (Fig. [1](#F1){ref-type="fig"} and Table [1](#T1){ref-type="table"}).

Immunohistochemical expression of GAD1 and its associations with clinicopathological parameters
-----------------------------------------------------------------------------------------------

As demonstrated in Table [2](#T2){ref-type="table"}, the 124 patients with NPC involved 95 males and 29 females, with a mean age of 48.6 years (range, 20-83 years). Moreover, 38 patients were classified as stage I-II and 86 as stage III-IV. Although GAD1 immunoreactivity was negligible in the non-tumorous nasopharyngeal epithelium with and without squamous metaplasia (Figs. [2](#F2){ref-type="fig"}a and 2b), it was discernible in certain tumor samples (Figs. [2](#F2){ref-type="fig"}c and 2d) and was significantly associated with the evaluated primary tumor status (*p* \< 0.001) and advanced AJCC stages (*p* = 0.002). However, GAD1 immunoexpression was not associated with other clinicopathological variables including histological types. Of note, in six patients whose primary and metastatic tumor lesions were available, the metastatic depositions demonstrated significant higher GAD1 expression than their primary tumors (*p*=0.015, Fig. [2](#F2){ref-type="fig"}e and 2f, respectively).

Prognostic effect of GAD1 expression
------------------------------------

The mean follow-up duration was 67 months (range, 3-141 months). For those three analyzing survival endpoints (Table [3](#T3){ref-type="table"}), patients with T3-4, N2-3, and AJCC stage III-IV tumors at the initial presentation were significantly correlated with poor outcomes in the univariate analysis. High GAD1 expression in patients with NPC was also a predictor of an aggressive clinical course, with significantly short DSS (*p* = 0.0002, Fig. [3](#F3){ref-type="fig"}a), DMeFS (*p* \< 0.0001, Fig. [3](#F3){ref-type="fig"}b), and LRFS (*p* = 0.001, Fig. [3](#F3){ref-type="fig"}c) rates. In the multivariate comparison (Table [4](#T4){ref-type="table"}), in addition to AJCC stages III-IV, high GAD1 expression remained an independent prognosticator for DSS (*p* = 0.004, hazard ratio = 2.234), DMeFS (*p*\< 0.001, hazard ratio = 4.218), and LRFS (*p*= 0.013, hazard ratio = 2.441).

Discussion
==========

Nearly 15%-20% of patients with NPC have distant metastasis, even after receiving concurrent chemoradiation therapies, accounting for the majority of disease mortality [@B1], [@B11], [@B33], [@B34]. Therefore, developing more effective treatments for effectively managing high-risk patients by stratifying and identifying prognostic and predictive biomarkers for invasive cancer cells is imperative. We re-examined differentially expressed genes in a published transcriptome data set, and we determined that the *GAD1* gene was the most significantly upregulated one among the DNA topological change-associated genes in NPC tissues. Our study is the first to report that GAD1 immunoexpression is associated with differential expression levels in NPC cases. In particular, GAD1 overexpression was significantly associated with increased primary tumor status levels and AJCC stages III-IV, and it appeared to be a prognosticator of adverse outcomes of DSS, DMeFS, and LRFS in the univariate analysis. Moreover, GAD1 overexpression, together with advanced AJCC stages III-IV, remained prognostically independent for low DSS, DMeFS, and LRFS rates in the multivariate comparison.

Previous evidence indicate that EBV infection plays an oncogenic role in the tumorigenesis of NPC [@B5]. Non-keratinizing carcinoma (differentiated or undifferentiated) is consistently associated with EBV infection with high reported infection up to 98% of all NPCs, and accounts for the majority in endemic regions such as Taiwan [@B35]. In our study, 119 out of 124 cases were classified as non-keratinizing or undiffereintated carcinoma NPCs and all NPC cases (except one) were identified to express EBER, thus supporting the previously validated results. The only one EBER-negative NPC was as a keratinizing squamous cell carcinoma. However, we could not demonstrate the prognostic significance of EBER status and high GAD1 expression because of the high prevalence of EBV infection in Taiwan. Notably, the WHO-classification-based histological stratification failed to demonstrate a significant statistical prognosticator in the univariate analysis. Although most of the analyzed cases (n=119) were classified as non-keratinizing carcinoma (differentiated or undifferentiated), only five cases were diagnosed with keratinizing carcinoma. It was unable to show statistical significance when dichotomized into low and high GAD1 expression according to the histologic subtypes. Kimura et al. [@B16] identified that GAD1 overexpression was associated with tumor invasiveness metastasis of OSCC and no differences were noted between the histopathological grade. We therefore hypothesized that high GAD1 expression was correlated with advanced NPC regardless of the histologic subtypes.

GABA was originally discovered as a primarily inhibitory neurotransmitter present in the mammalian brain [@B36]. The dysregulation of GABA and GAD1 has been reported to be associated with several neuronal diseases such as schizophrenia, bipolar disorder, Parkinson disease, and cerebellar disorders [@B22], [@B37]. Moreover, GABA and GAD1 levels are considerably increased in several solid organ cancers including oral, breast, gastric, and colorectal cancers, although heterogeneity exists in the extent of overproduction among such cancers [@B16], [@B21], [@B22]. In the current study, we also found that a high GAD1 expression level was correlated with advanced-stage cancer, including the development of distant metastasis, and shorter survival rates in patients with NPC. This implies that an altered GAD1 expression level plays a critical role in tumor invasiveness. Yan et al. [@B22] recently elucidated that DNA methylation in the GAD1 promoter region plays a pivotal role in GAD1 activation in cancer cells; they also identified increased GAD1 expression levels in mucinous colon cancer, and this increase has been revealed to result in poor responses to 5-fluorouracil-, oxaliplatin-, and irinotecan-based regimens [@B22], [@B38], [@B39]. These results are similar to our findings.

Our results are further supported by those of studies focusing on the proliferative effects of GABA on neoplastic cells and the GAD1 and GABA receptor expression in several malignancies [@B40]-[@B43]. It implied that a metabolic antagonist that converts glutamate into GABA, but not glutamine, is preferred for neoplasms with poor outcomes [@B44]. Furthermore, increased GABA expression and GAD activity may be involved in the invasiveness of prostate cancer cells [@B21], [@B23]. Previous reports have also revealed that GAD1 can serve as a specific marker for prostate tissues [@B24], [@B44]. Jaraj et al. [@B24] identified that GAD1 is expressed in both benign and malignant prostate tissues, with a negative correlation with an increasing Gleason score, thus implying that GAD1 is a negative prognosticator. This result is different from our results that reveal that the observed high GAD1 expression was associated with increased primary tumor status levels and advanced disease stages. In general, higher Gleason scores are correlated with poor disease outcomes in patients with prostate cancers [@B45]. However, a considerable interobserver discrepancy was observed in grading the Gleason score, and a new grading system for simplifying the previously reported patterns is proposed in the International Society of Urological Pathology Urological Pathology Consensus Conference [@B45]. This may partially explain the discrepancy between the data of the present study and those reported by Jaraj et al. [@B24].

Kimura et al. [@B16] proposed that the GAD1/β-catenin/MMP7 interaction may play crucial and diverse roles in the early detection of nodal metastasis and that it may serve as an effective treatment target for preventing distant metastasis in OSCCs. This interaction has been demonstrated to be β-catenin centric and crucial in Wnt signal transduction, gene activation and neoplasm [@B46]-[@B48]. Furthermore, several studies have identified that β-catenin is not only be involved in cell proliferation and survival but may also play an essential role in the development of metastases in some malignancies including NPC [@B49]-[@B50]. Although the mechanisms of GAD1 and β-catenin remain unclear, Kimura et al. [@B16] suggested that GAD1 expression can control β-catenin localization that further activates the downstream genes playing key roles in tumorigenesis and metastasis. These findings may further support the identification of GAD1 overexpression is correlated with advanced NPC diseases in the current study. Although this factor remains unclear, it can serve as a treatment target for advanced-stage NPC patients with resistance to cisplatin-based radiotherapy to enable them benefit from investigatory small β-catenin inhibitors [@B51]. Moreover, the glutamine-glutamate/GABA cycle influences GABA metabolism through GAD1 [@B15]. Li et al. [@B52] reported an overexpression of GABA and GABA receptors in hepatocellular carcinoma. Hence, on the basis of our findings, we suggest incorporating GABAergic system agonists into adjuvant therapy for patients with advanced NPC.

In this present study, we did not investigate endogenous GAD1 mRNA and protein levels in NPC through Western blot or reverse transcription polymerase chain reaction that could further support the observed high GAD1 expression as a poor prognosticator. A large-scale study is required to clarify the association between the GAD1 protein and β-catenin expression in NPC.

In conclusion, this study is the first to report that GAD1 overexpression is associated with an advanced tumor status. Furthermore, the overexpression serves as a critical prognosticator of early local recurrence and distant metastasis in patients with early and locoregionally advanced NPC. Our findings strengthen the potential role of GAD1 in contributing to tumor invasiveness in NPC and reveal that GAD1 is a novel therapeutic target for treatment.
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![Photomicrographs of GAD1 immunoexpression. In normal nasopharyngeal mucosa with (A, X200) and without (B, X400) squamous metaplasia, there is nearly no or faint immunopositivity with GAD1. In NPC tissues, the tumor cells show weak (C, X400) or diffusely strong (D, X400) staining of GAD1 marker in representative low- and high-expression cases, respectively. Evaluation of GAD1 expression in representative primary NPC tissue (E, X400) and metastatic nodal tissue (F, X400) demonstrates more diffusely strong staining result in the metastatic depositions.](jcav07p1716g002){#F2}
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###### 

Summary of prominent differentially expressed genes associated with glutamate decarboxylase activity (GO:0004351) and with tumorigenesis of nasopharyngeal carcinoma (NPC) in the NPC transcriptome (GSE12452).

  Probe          Comparing tumor to non-tumor   Gene Symbol   Gene Name   Molecular Function                         
  -------------- ------------------------------ ------------- ----------- ------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------
  205278_at      2.4426                         \<0.0001      *GAD1*      glutamate decarboxylase 1 (brain; 67kDa)   carboxy-lyase activity, catalytic activity, glutamate decarboxylase activity, lyase activity, protein binding, pyridoxal phosphate binding
  206669_at      0.6126                         0.0015        *GAD1*      glutamate decarboxylase 1 (brain; 67kDa)   carboxy-lyase activity, catalytic activity, glutamate decarboxylase activity, lyase activity, protein binding, pyridoxal phosphate binding
  206670_s\_at   0.3746                         0.0009        *GAD1*      glutamate decarboxylase 1 (brain; 67kDa)   carboxy-lyase activity, catalytic activity, glutamate decarboxylase activity, lyase activity, protein binding, pyridoxal phosphate binding

###### 

Associations between GAD1 expression and other crucial clinicopathological variables.

  Parameters           Category           GAD1 Exp.   p-value   
  -------------------- ------------------ ----------- --------- -----------
  Gender               Male               46          49        0.524
                       Female             16          13        
  Age (years)          \<60 years         47          51        0.378
                       \>=60 years        15          11        
  Primary tumor (pT)   T1-T2              50          30        \<0.001\*
                       T3-T4              12          32        
  Nodal status (N)     N0-N1              35          21        0.012
                       N2-N3              27          41        
  Stage                I-II               27          11        0.002\*
                       III-IV             35          51        
  Histological grade   Keratinizing       2           3         0.728
                       Non-keratinizing   29          25        
                       Undifferentiated   31          34        
  EBER                 Negative           0           1         0.315
                       Positive           62          61        

\*, Statistically significant.

###### 

Univariate log-rank analyses.

  Parameters           Category                        No. of case   DSS   DMeFS      LRFS                     
  -------------------- ------------------------------- ------------- ----- ---------- ------ ------------ ---- ----------
  Gender               Male                            95            45    0.7870     38     0.6128       30   0.3240
                       Female                          29            14               11                  7    
  Age (years)          \<60 years                      98            48    0.8600     42     0.3091       29   0.8206
                       \>=60 years                     26            11               7                   8    
  Primary tumor (pT)   T1-T2                           80            32    0.0289\*   25     0.0085\*     19   0.0180\*
                       T3-T4                           44            27               24                  18   
  Nodal status (N)     N0-N1                           56            18    0.0008\*   17     0.0132\*     12   0.0160\*
                       N2-N3                           68            41               32                  25   
  Stage                I-II                            38            10    0.0020\*   9      0.0072\*     5    0.0026\*
                       III-IV                          86            49               40                  32   
  Histological grade   Keratinizing/Non-keratinizing   47            20    0.1980     17     0.2753       15   0.9521
                       Undifferentiated                77            39               32                  22   
  EBER                 Negative                        1             1     0.0577     1      0.0937       0    0.7305
                       Positive                        123           58               48                  37   
  GAD1 Exp.            Low Exp. (H-score\<median)      62            20    0.0002\*   11     \<0.0001\*   12   0.0010\*
                       High Exp. (H-score\>=median)    62            39               38                  25   

\*, Statistically significant; DSS, disease-specific survival; DMeFS, distal metastasis-free Survival; LRFS, local recurrence-free survival

###### 

Multivariate survival analyses.

  Parameter   Category    DSS     DMeFS         LRFS                                                              
  ----------- ----------- ------- ------------- --------- ------- ------------- ----------- ------- ------------- ---------
  Stage       I-II        1       \-            0.023\*   1       \-            0.121       1                     0.023\*
              III-IV      2.246   1.118-4.513             1.796   0.856-3.769               3.057   1.168-8.002   
  GAD1 Exp.   Low Exp.    1       \-            0.004\*   1       \-            \<0.001\*   1       \-            0.013\*
              High Exp.   2.234   1.284-3.887             4.218   2.121-8.389               2.441   1.207-4.935   

\*, Statistically significant; DSS, disease-specific survival; DMeFS, distal metastasis-free Survival; LRFS, local recurrence-free survival
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